Comment
doi: 10.1038/nrurol.2014.98.
Epub 2014 Apr 29.
Prostate cancer: enzalutamide impresses in European studies
- PMID: 24776976
- DOI: 10.1038/nrurol.2014.98
Item in Clipboard
Comment
Prostate cancer: enzalutamide impresses in European studies
Nat Rev Urol.
2014 May.
No abstract available
Comment on
-
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.Lancet Oncol. 2014 May;15(6):592-600. doi: 10.1016/S1470-2045(14)70129-9. Epub 2014 Apr 14. Lancet Oncol. 2014. PMID: 24739897 Clinical Trial.
Similar articles
-
Prostate cancer: enzalutamide PREVAILs.Nat Rev Urol. 2014 Jul;11(7):361. doi: 10.1038/nrurol.2014.139. Epub 2014 Jun 17. Nat Rev Urol. 2014. PMID: 24934449 No abstract available.
-
Anti-androgen monotherapy for metastatic prostate cancer.Lancet Oncol. 2014 May;15(6):543-4. doi: 10.1016/S1470-2045(14)70159-7. Epub 2014 Apr 14. Lancet Oncol. 2014. PMID: 24739898 No abstract available.
-
Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med. 2014 Oct 30;371(18):1755. doi: 10.1056/NEJMc1410239. N Engl J Med. 2014. PMID: 25354112 No abstract available.
-
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.Nat Rev Urol. 2016 Dec;13(12):697-698. doi: 10.1038/nrurol.2016.212. Epub 2016 Nov 2. Nat Rev Urol. 2016. PMID: 27804988 Review. No abstract available.
-
The role of enzalutamide in the treatment of castration-resistant prostate cancer.Future Oncol. 2012 Sep;8(9):1073-81. doi: 10.2217/fon.12.99. Future Oncol. 2012. PMID: 23030482 Review.
Cited by
-
Prostate cancer: enzalutamide PREVAILs.Nat Rev Urol. 2014 Jul;11(7):361. doi: 10.1038/nrurol.2014.139. Epub 2014 Jun 17. Nat Rev Urol. 2014. PMID: 24934449 No abstract available.
References
-
- Lancet Oncol. 2014 May;15(6):592-600 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
